Tumor Dormancy and Cell Signaling. V. Regrowth of the BCL1 Tumor After Dormancy Is Established

Author:

Vitetta Ellen S.1,Tucker Thomas F.1,Racila Emilian1,Huang Yi-Wu1,Marches Radu1,Lane Nancy1,Scheuermann Richard H.1,Street Nancy E.1,Watanabe Takeshi1,Uhr Jonathan W.1

Affiliation:

1. From the Cancer Immunobiology Center and Departments of Microbiology and Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX; and the Department of Molecular Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

Abstract

AbstractThe majority of BALB/c mice immunized with the BCL1 lymphoma-derived idiotype (Id+) IgM and subsequently challenged with BCL1 tumor cells develop a state of tumor dormancy. The vast majority of dormant lymphoma cells are in cell cycle arrest, but there are also residual replicating cells. In the present studies, we attempted to define features of both the dormant lymphoma cells and the host that lead to escape from dormancy. Escape from dormancy occurs at a steady rate over a 2-year period, suggesting that it is a stochastic process. We found that, in the majority of mice, escape was due to the emergence of genetic variants that were no longer susceptible to the anti-Id–mediated induction of dormancy. Ten percent of these variants were Id−; the remainder were Id+ but could grow in the presence of anti-Id antibodies, suggesting that there were mutations in molecules involved in one or more mIg-mediated negative-signaling pathways. In two of five such escapees, alterations in either Syk, HS1, and/or Lyn were observed. In a small percentage of mice, a low titer of circulating anti-Id antibody before tumor challenge correlated with a subsequent, more rapid loss of dormancy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference85 articles.

1. Tumor dormancy initiation, maintenance and termination in animals and humans.;Stewart;Can J Surg,1991

2. Dormancy and breast cancer.;Meltzer;J Surg Oncol,1990

3. The dormant cancer cell.;Hadfield;Br Med J,1954

4. The tumor dormant state.;Wheelock;Adv Cancer Res,1981

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3